178 related articles for article (PubMed ID: 37403746)
21. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
23. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
24. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
25. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
26. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R; Diéras V; Pivot X; Brain E; Roché H; Extra JM; Monneur A; Provansal M; Tarpin C; Bertucci F; Viens P; Zemmour C; Gonçalves A
Cancer Res Treat; 2018 Oct; 50(4):1226-1237. PubMed ID: 29281873
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
Mougalian SS; Kish JK; Zhang J; Liassou D; Feinberg BA
Adv Ther; 2021 May; 38(5):2213-2225. PubMed ID: 33491157
[TBL] [Abstract][Full Text] [Related]
28. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.
De Luca R; Alù M; Genova G; Grassadonia A; Cicero G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12727-12734. PubMed ID: 33378020
[TBL] [Abstract][Full Text] [Related]
29. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
30. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
Watanabe J
Springerplus; 2015; 4():625. PubMed ID: 26543760
[TBL] [Abstract][Full Text] [Related]
31. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Muss H; Cortes J; Vahdat LT; Cardoso F; Twelves C; Wanders J; Dutcus CE; Yang J; Seegobin S; O'Shaughnessy J
Oncologist; 2014 Apr; 19(4):318-27. PubMed ID: 24682463
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
34. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
La Verde N; Damia G; Garrone O; Santini D; Fabi A; Ciccarese M; Generali DG; Nunzi M; Poletto E; Ferraris E; Cretella E; Scandurra G; Meattini I; Bertolini AS; Cavanna L; Collovà E; Romagnoli E; Rulli E; Legramandi L; Guffanti F; Bramati A; Moretti A; Cassano A; Vici P; Torri V; Farina G;
Breast Cancer Res; 2022 Oct; 24(1):71. PubMed ID: 36307826
[TBL] [Abstract][Full Text] [Related]
35. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
36. Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.
Jafri M; Kristeleit H; Misra V; Baxter M; Ahmed S; Jegannathen A; Jain A; Maskell D; Barthakur U; Edwards G; Walter HS; Walshaw R; Khan M; Borley A; Rea D
Oncology; 2022; 100(12):666-673. PubMed ID: 36044833
[TBL] [Abstract][Full Text] [Related]
37. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
J BUON; 2020; 25(2):641-647. PubMed ID: 32521847
[TBL] [Abstract][Full Text] [Related]
38. Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
De Sanctis R; Agostinetto E; Masci G; Ferraro E; Losurdo A; Viganò A; Antunovic L; Zuradelli M; Torrisi RMC; Santoro A
Oncology; 2018; 94 Suppl 1(Suppl 1):19-28. PubMed ID: 30036884
[TBL] [Abstract][Full Text] [Related]
39. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
Front Oncol; 2020; 10():271. PubMed ID: 32195186
[No Abstract] [Full Text] [Related]
40. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Takashima T; Tokunaga S; Tei S; Nishimura S; Kawajiri H; Kashiwagi S; Yamagata S; Noda S; Nishimori T; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K
Springerplus; 2016; 5():164. PubMed ID: 27026861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]